Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Novel Oncology Drugs in Clinical Development in SWITZERLAND

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              F. Hoffmann-La Roche

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              3rd Formulation & Drug Delivery USA

              Participation Not Confirmed

              Update your events

              Celleron Therapeutics Enters Into a Iicense Agreement with Roche to Improve the Lives of Patients Living with Tenosynovial Giant Cell Tumour

              Contact the Supplier

              Lead Product(s): Emactuzumab

              Therapeutic Area: Oncology Product Name: RG7155

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Celleron

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 12, 2020

              Details:

              Roche to provid Celleron exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab. Emactuzumab is a monoclonal antibody designed to target and deplete macrophages in the tumor tissue.

              Novartis Pharmaceuticals Corporation

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              3rd Formulation & Drug Delivery USA

              Participation Not Confirmed

              Update your events

              Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

              Contact the Supplier

              Lead Product(s): IOV-3001

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Iovance Biotherapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 12, 2020

              Details:

              Iovance Biotherapeutics will use TALEN® Technology from cellectis to develop gene-edited TIL.

              PharmaCompass__DigitalAd